All In Biotech

Drug Trial Radar · NCT00589875

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas

Last checked: Nov 20, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Mar 2007

Primary completion

Dec 2015

Study completion Aug 2016

Sponsor

Lead sponsor
Candel Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. CAN-2409 was injected into the resection bed after standard tumor surgery and valacyclovir pills were taken for 14 days. Standard radiation and chemotherapy were administered which have been shown to work cooperatively with CAN-2409 + prodrug to kill tumor cells. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with newly diagnosed malignant gliomas, including glioblastoma multiforme (WHO grade IV) and anaplastic astrocytomas (WHO grade III).

Conditions

  • Malignant Glioma
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • High Grade Glioma

Interventions

  • CAN-2409Biological

    Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.

  • ValacyclovirDrug

    Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3

  • TemozolomideDrug

    Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.

  • Radiation therapyRadiation

    Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Related Adverse EventsTime frame: 2 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

  • The University of Chicago

    Chicago, Illinois

  • The Ohio State University Medical Center, Dept. Neurological Surgery

    Columbus, Ohio

  • The Methodist Hospital Neurological Institute

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.